^
Association details:
| Biomarker: | BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
Published date:
01/18/2023
Excerpt:
Histological examination of paraffin-embedded (FFPE) specimens from surgically removed tumor tissue led to a pathological diagnosis of stage II (cT2N0M0) ICC...The patient was identified to harbor four somatic genetic variations, including BAP1 mutation (Q40*), IDH2 mutation (R172W) as well as the co-deletion of CDKN2A and CDKN2B genes...The palbociclib treatment (125 mg daily for 21 days, then 7 days off) was subsequently started...These indicated that the patient had a good response to palbociclib treatment.
